Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition

Trending

• Fierce Biotech6 months ago

  Scientists turn pig semen extract into eye drops that kill cancer in mice

• Endpoints News6 months ago

  Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation

• Uncategorized6 months ago

  Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion

• Nature Biotechnology6 months ago

  Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy

• Uncategorized5 months ago

  Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells

• Uncategorized4 months ago

  Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study